Please ensure Javascript is enabled for purposes of website accessibility
Cory Renauer

Cory Renauer


Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.

Recent articles


3 Beaten-Down Biotech Stocks: Can They Recover?

These drugmaker stocks may have been hammered down to bargain-bin prices.


Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns

The odds of experiencing a fatal blood clot following inoculation with AstraZeneca's COVID-19 vaccine are less than one in a million, but that was enough to spook Argus Research.


3 Biotech Stocks With Big Catalysts Around the Corner

Upcoming events could send these stocks screaming higher or lower.


This Unstoppable Stock Doesn't Pay a Dividend Yet, but It Could

This giant of the genomic revolution ticks nearly all the boxes dividend investors should look for.


Is Illumina Still a Good Stock to Buy?

The company's attempts to grow through acquisition keep running into problems.


11 Words From President Biden That Frighten Big Pharma

This is why America's largest pharmaceutical companies are nervous about the American Jobs Plan.


Forget the Vaccine Problems, AstraZeneca Stock Can Still Make You Rich

There's a lot more to AstraZeneca than poorly presented vaccine data.


Co-Diagnostics: Buy the Dip?

Analysts following this coronavirus stock have darkened their post-pandemic outlook.


6 Words From Pfizer's CEO That Mean Trouble for Moderna and BioNTech

It looks like the proprietary technology that led to the first COVID-19 vaccines isn't very difficult to replicate.


Pfizer to Develop mRNA Vaccines Without BioNTech

The pharmaceutical heavyweight thinks it won't need any more help to whip up new mRNA-based vaccines.


Before You Buy Zomedica Stock, Stop and Consider These 3 Things

There are a few things you should know before risking your hard-earned money on this stock.


Should You Buy Cassava Sciences Stock Now?

A potential new treatment for Alzheimer's disease could be worth billions.


3 Biotech Stocks to Avoid Right Now

Here's why these attention-grabbing stocks could be toxic to your portfolio.


Disruptor Alert: Amazon Care Will Soon Be Available to All U.S. Amazon Employees

The virtual-care service that launched in Seattle is going nationwide.


Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing

Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.


3 Biotech Stocks That Have Already Rocketed Higher in 2021

Here's why these highfliers could have more fuel in the tank.


Pfizer's Vaccine 97% Effective at Preventing COVID-19 in Real-World Study

Results from Israel suggest the Pfizer-BioNTech vaccine works even better than its phase 3 trial results indicated.


Does Eli Lilly Have a New Blockbuster Weight Loss Drug?

Late-stage trial results suggest a potential new diabetes drug also helps people lose a lot more weight than Novo Nordisk's semaglutide.


Can Fulgent Genetics Stock Rebound?

New COVID-19 tests catapulted this company to fame, but investors are worried about what happens next.


Amgen to Buy Oncology Start-Up Five Prime Therapeutics for $1.9 Billion

The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.